Robert W. Baird Boosts Immutep (NASDAQ:IMMP) Price Target to $7.00

Immutep (NASDAQ:IMMP) had its target price boosted by Robert W. Baird from $6.00 to $7.00 in a report published on Friday morning,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

Immutep Stock Down 1.9 %

Shares of Immutep stock traded down $0.04 during midday trading on Friday, reaching $2.05. The company had a trading volume of 219,746 shares, compared to its average volume of 220,215. The stock has a fifty day moving average price of $2.10 and a 200 day moving average price of $2.33. Immutep has a fifty-two week low of $1.58 and a fifty-two week high of $3.34. The company has a debt-to-equity ratio of 0.01, a current ratio of 18.25 and a quick ratio of 18.25.

Institutional Investors Weigh In On Immutep

Several large investors have recently modified their holdings of the company. XTX Topco Ltd bought a new position in shares of Immutep during the 2nd quarter worth approximately $26,000. BNP Paribas Financial Markets increased its stake in Immutep by 15.4% in the first quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock valued at $82,000 after purchasing an additional 4,700 shares in the last quarter. Virtu Financial LLC boosted its position in shares of Immutep by 269.4% during the 1st quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 32,864 shares in the last quarter. XY Capital Ltd acquired a new stake in shares of Immutep in the 2nd quarter valued at about $105,000. Finally, Meridian Wealth Management LLC increased its holdings in shares of Immutep by 4.5% during the third quarter. Meridian Wealth Management LLC now owns 398,450 shares of the biotechnology company’s stock valued at $881,000 after acquiring an additional 17,250 shares in the last quarter. 2.32% of the stock is currently owned by institutional investors and hedge funds.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.